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Abstract
Introduction. Cervical cancer is caused by human papillomavirus (HPV), but some cases may test HPV- negative. We previously 
tested 2850 Swedish cases and found that 394/2850 (13.8 %) cases tested HPV DNA- negative by PCR. Sequencing is the most 
thorough method to assess HPV status.
Aim. We wished to assess whether deep sequencing might detect HPV sequences among these HPV- negative cervical cancer 
specimens, and to increase the likelihood of detecting transcriptionally active infections.
Methodology. Out of the 2850 cancer cases, we sequenced a random sample of 92 HPV PCR- negative cervical cancers and 34 
HPV PCR- positive cervical cancers. Four pools of blank blocks were sequenced as negative controls. To enrich for mRNA – a 
hallmark of active viral infection – the samples were extracted, reverse- transcribed, rRNA- depleted and then sequenced using 
the NovaSeq 6000 system (Illumina, USA). High- quality reads were aligned to the human genome and non- human reads were 
queried against HPV proteins.
Results. We obtained a median of 23 million paired reads per sample. HPV was detected in 31/34 HPV PCR- positive cases. 
Among cases negative for HPV by PCR, 48/92 (52.2 %) contained HPV sequences, with HPV33 being the most commonly detected 
type among these (14/48 cases, 29.2 %). Comparison of the ratio of exon and intron sequences found that the sequenced mate-
rial contained both DNA and RNA. Splice junctions were detected in 12 cases.
Conclusion. Apparently, some cervical cancers contain HPV that is difficult to detect by PCR. Sequencing may be a helpful tool 
for additional quality assurance for HPV testing methods.
InTRoduCTIon
Human papillomavirus (HPV) is the major cause of cervical 
cancer. The usual methods to screen for HPV- associated 
lesion and cancers are based on PCR, usually targeting the 
L1 gene, which is the most conserved gene within the HPV 
genome [1]. PCR methods are both efficient and sensitive, 
but are also biased to only detect HPVs that bind specifically 
to designed primers and probes. HPV types that diverge in 
their nucleotide sequences from the primers/probe sequences 
may escape amplification and will remain undetected [2]. For 
optimal cervical screening, it is essential to as far as possible 
limit the risk of false- negative tests. Previous studies have 
shown that cervical cancers testing HPV- negative by PCR 
constitute a biologically distinct subgroup, associated with 
symptomatic detection, late- stage diagnosis and worse prog-
nosis [3].
With the dramatically decreased cost of sequencing, it is now 
easy to perform sequencing of samples and with bioinfor-
matics detect all HPVs present in a sample, without prior 
knowledge of which types might be present [2, 4, 5]. Unbiased 
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analysis of the nucleic acid sequences will detect any HPV 
type present in the sample, with no need to design primers 
and probes for previously known sequences. Sequencing of 
mRNA is of particular interest, as it will show if the HPV 
that is present has transcriptional activity. Viral oncogene 
transcription is essential for both initiation and maintenance 
of the malignant phenotype.
We wished to assess whether cervical cancer specimens testing 
HPV- negative by PCR may still contain HPV sequences that 
can be found by sequencing. Through the generation of cDNA 
prior to sequencing, we further aimed to increase the likeli-
hood of detecting transcriptionally active infections.
METHodS
Sample material
Previously [6], we identified and requested formalin- fixed, 
paraffin- embedded (FFPE) blocks from all invasive cervical 
cancers in Sweden from 2002 to 2011 (n=4254). All obtained 
blocks (n=2932) were extracted with a xylene- free method 
and the nucleic acid extracts were stored at −20 °C [7].
A total of 2850/2932 cancers had adequate HPV typing 
results, with 394/2850 (13.8 %) cases being ‘apparently HPV- 
negative’ after being tested for HPV DNA with both PCR with 
MGP primers targeting the L1 gene, and real- time PCR with 
primers targeting the E7 gene for HPV16, and the E6 gene 
for HPV18 [6].
Out of these 394 cases, we included a randomly selected 
sub- set of cervical tumour specimens. We analysed a total of 
136 samples, including 34 HPV- positive cervical specimens 
(L1 positive for PCR) used as positive controls, 92 ‘appar-
ently HPV- negative’ cervical specimens, 4 pools comprising 
all blank blocks from all tumour blocks as negative controls 
and 6 duplicates to evaluate the reproducibility of the study. 
Blank blocks from each case block, both positive and negative 
for HPV, had been picked out and pooled into four negative 
control pools.
Sequencing
All 136 samples (126 specimens, 6 duplicates and 4 blank 
blocks) were extracted [7], reverse- transcribed, ligated to 
individual adapters and rRNA- depleted using the SMARTer 
pico kit according to the manufacturer’s protocol (Takara, 
USA). Libraries were validated, normalized to 2 nM and 
pooled before sequencing. Sequencing was performed using 
the NovaSeq 6000 system (Illumina, USA), 2×150 bp, in 
two different runs. The first sequencing run comprised 30 
HPV- positive specimens, 33 cancer specimens that had been 
HPV- negative by PCR and 2 pools containing all blank blocks 
from these 63 specimens. Sequencing was performed on 2 S1 
lanes aiming for 2000 million paired reads (30 M paired reads 
per sample). The second sequencing run comprised 5 HPV- 
positive specimens, 64 apparently HPV- negative cancer speci-
mens and 2 pools containing all blank blocks from these 69 
specimens. The six duplicates used for reproducibility testing 
were already included among these samples. Duplicates 
corresponded to one HPV16 PCR- positive specimen and 5 
HPV PCR- negative specimens. Sequencing was performed 
on 1 S4 lane aiming for 2000–2500 million paired reads (30 
M paired reads per sample). Pools containing blank blocks 
were made randomly.
Bioinformatic analysis
Indices, included in the Illumina adaptors, were used to 
assign raw sequence reads obtained from the NovaSeq 
6000 (Illumina) platform to the originating samples. Reads 
were quality- and adaptor- trimmed with Trimmomatic [8]. 
All reads with a read length below 18 base pairs (bp) were 
discarded for further analysis and the first 3 nucleotides 
from every R2 read were trimmed, as indicated within the 
SMARTer pico kit used for library preparation. High- quality 
reads were screened against the human reference genome 
GRCh38 using NextGenMap [9] and human reads (reads 
mapping with >95 % identity over 75 % of their length) were 
filtered from the data set. Non- human reads were queried 
against all HPV protein sequences included in the PaVE 
database (Papillomavirus Episteme, accessed on 28 July 
2019, including all protein sequences from HPV reference 
and non- reference genomes), using the open source software 
Diamond [10] blastx with default parameters and –top 1. 
Samples were considered positive for HPV if a minimum of 
five reads were detected for any HPV type with at least 90 % 
identity. Samples presenting a co- infection of HPV types were 
subjected to manual investigation to confirm positivity for the 
corresponding genotypes in order to avoid false positivity due 
to both genotypes presenting close phylogeny.
Confirmation of HPVs with a low number of reads
Sequenced specimens that were positive with a low number 
of reads for an HPV type that had been present in another 
specimen at a high number of reads in the same sequencing 
run were selected for independent verification. Misclassifica-
tion of index sequences, (particularly if the sequences are of 
low quality) may result in erroneous assignment of sequence 
reads to the wrong sample (so- called ‘index hopping’) [11]. 
Samples that presented <2 % of the reads found in another 
specimen analysed in the same run were either confirmed with 
previous genotyping results or resequenced. Resequencing 
was performed using new libraries (the same protocol as 
described above) and sequencing with the NextSeq 500 
system (Illumina, USA) at 151 paired- end cycles, according 
to manufacturer’s instructions.
Analysis of dnA and cdnA amounts in the 
sequenced samples
Because the nucleic acid extraction method used is not specific 
for DNA or RNA and the reverse transcription method used 
to obtain cDNA does not contain any DNA depletion step, 
we wished to assess whether the sequences obtained were 
derived mostly from genomic DNA or from cDNA. The reads 
were mapped to introns and exons of the human reference 
protein coding gene, actin beta (ACTB). The presence of 
cDNA was also studied by analysing whether there were reads 
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that contained sequences known to represent splice junction 
sequences for viral mRNAs.
RESuLTS
One hundred and twenty- six cervical cancer specimens 
(34 HPV- positive and 92 apparently HPV- negative) were 
sequenced using NovaSeq 6000 (Illumina, USA) and analysed 
bioinformatically for HPV detection. The median age at 
diagnosis of the cases was 60 years (range 25–95 years); most 
women were aged 43–74 at diagnosis. Seventy- eight per cent 
of the cases had squamous cell carcinoma, 14 % had adenocar-
cinoma and 8 % were diagnosed with rarer histological types, 
such as adenosquamous carcinoma. Compared to cases origi-
nally positive by HPV PCR, cases originally HPV- negative 
were generally older and more often presented with a higher 
stage (III+) at diagnosis (Table 1).
The sequencing generated high- quality sequencing data, with 
a median of 1800 M paired reads per run and 23 M paired 
reads per sample. Most reads present in the specimens (an 
average of 95 % of the total reads) were human sequences.
We found HPV sequences in 31/34 specimens originally 
designated positive by HPV PCR, with total concord-
ance regarding the HPV type detected in 29/31 specimens 
(Table 2). Partial concordance was detected in one specimen. 
This cervical tumour had been genotyped as HPV16, but 
sequencing found both HPV16 and HPV40 sequences. In 
3/34 HPV- positive specimens we did not find HPV sequences 
of the type detected by PCR. One specimen that had been 
genotyped as HPV16 was found to contain sequences from 
both HPV33 and HPV73. Confirmation of HPV co- infections 
in HPV- positive specimens (n=3) was performed by blasting 
and visualizing reads manually (Table 2).
We further found HPV sequences in 48/92 specimens origi-
nally deemed negative by HPV PCR (52.2%). Almost all posi-
tive specimens contained sequences from only a single HPV 
type (93.8%, 45/48). HPV33 and 73 were the most common 
types detected (14/48 and 8/48, respectively) (Table 3). As 
13 of the 17 different HPV types detected should have been 
detected by the PCR- based method, we analysed the coverage 
of HPV reads within the MGP region in the L1 gene (the PCR 
region targeted for genotyping) as well as possible mismatches 
with primers and probes (Table 3). Twenty- nine specimens 
(29/48, 60.4%) showed HPV genotypes with no reads at 
all covering the MGP region. Two HPV types from the 19 
specimens that did contain reads in the MGP region instead 
presented nucleotide substitutions when their sequence was 
compared with the respective HPV reference clone used for 
MGP optimization [12] and the probe (Table 3).
Sequences from several HPV types were detected in three 
samples that contained sequences from HPV31/58, HPV31/62 
and HPV4/53/203, respectively. Confirmation of the presence 
of multiple different HPV types within the same specimen 
was performed by blasting and visualizing reads manually. 
None of the blank blocks used as negative controls presented 
any reads belonging to the HPV genotypes present within 
the specimens.
Six specimens were extracted and subjected to library prepa-
ration and sequencing twice (so- called duplicates) to assess 
reproducibility of the study. These included one HPV16 PCR- 
positive specimen and five HPV PCR- negative specimens. 
Novaseq confirmed HPV16 positivity in the corresponding 
HPV16 PCR- positive specimen as well as HPV negativity in 
4/5 HPV PCR- negative specimens. One specimen that had 
previously been classified as HPV PCR- negative was deemed 
positive in Novaseq sequencing (HPV33). All six duplicates 
presented the same result when resequenced.
Confirmation of HPVs with a low number of reads
To avoid false- positive results, in addition to checking whether 
any HPV type was found among all specimens in any of the 
four negative controls (blank blocks from all cancer cases), 
Table 1. Characteristics of cervical tumour specimens
HPV− 
(n=92)
HPV+ (n=34) Total 
(n=126)
Age at cancer diagnosis
  Median (range) 61 (26–91) 57.5 (25–95) 60 (25–95)
    <29 1 (1.1) 1 (2.9) 2 (1.6)
    30–44 23 (25.0) 9 (26.5) 32 (25.4)
    45–59 18 (19.6) 8 (23.5) 26 (20.6)
    60–74 27 (29.3) 8 (23.5) 35 (27.8)
    >74 23 (25.0) 8 (23.5) 31 (24.6)
FIGO stage
  IA 12 (13.0) 4 (11.8) 16 (12.7)
  IB 25 (27.2) 15 (44.1) 40 (31.7)
  II 17 (18.5) 8 (23.5) 25 (19.8)
  III+ 38 (41.3) 7 (20.6) 45 (35.7)
Cancer types*
  Squamous cell carcinoma 69 (75.0) 29 (85.3) 98 (77.8)
  Adenocarcinoma 15 (16.3) 3 (8.8) 18 (14.3)
  Adenosquamous cell 
carcinoma
4 (4.3) 1 (2.9) 5 (4.0)
  Other types† 4 (4.3) 1 (2.9) 5 (4.0)
The numbers in parentheses show the percentage of specimens, 
calculated as the number for each level divided by the total 
number of HPV− and HPV+ cases, respectively (e.g. 13 % of 
specimens that were HPV- negative were classified as FIGO stage 
IA).
*Cancers that were not primary, invasive, epithelial, or recurrent 
cases were excluded.
†Other cancer types, including small cell carcinoma, large cell 
carcinoma, neuroendocrine carcinoma and undifferentiated cell 
carcinoma.
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we considered whether the apparently PCR HPV- negative 
specimens that were deemed positive by sequencing and 
presented a low number of reads might have been mistakenly 
classified as HPV- positive due to a phenomenon known as 
‘index hopping’, where similar indexed adapters are misread 
during multiplexed sequencing, resulting in some sequences 
being assigned to the wrong sample.
Samples that presented <2 % of the HPV reads of another 
sample analysed in the same run (n=12/126; 8 HPV16, 3 
HPV33 and 1 specimen with HPV58) were analysed further 
for positivity verification (Table 4).
Genotyping results confirmed HPV16 and HPV58 positivity 
in 5/8 and 1/1 sample(s), respectively. We resequenced the 
other three HPV16- positive specimens and three HPV33 
specimens. Resequencing with NextSeq included one posi-
tive control, one negative control and 5/6 specimens (one 
HPV16 specimen could not be resequenced because there 
was not enough sample material left). HPV33 presence was 
confirmed in 3/3 analysed specimens. HPV16, however, was 
not detectable in 1/3 specimens and the other resequenced 
specimen showed the presence of HPV33 (3052 reads) but 
no trace of HPV16.
Analysis of dnA and cdnA amounts
Fragment analysis showed large gDNA molecules after extrac-
tion and the visualization of sequencing reads mapping the 
introns of the ACTB gene (Fig. S1, available in the online 
version of this article) confirmed the presence of DNA. The 
median exon/intron ratio – calculated as (reads covering the 
exons/total nucleotide length of exons)/(reads covering the 
introns/total nucleotide length of introns) – was 1.49 (max: 
9.31; min: 0.59). In order to confirm existence of cDNA, we 
looked for known splice junctions belonging to spliced HPV 
transcripts and detected reads with these splice junctions in 
12 specimens (Table 5). Negative blank blocks showed no 
reads in the ACTB gene, as expected.
dISCuSSIon
Cervical cancer is caused by HPV, but a proportion of cervical 
carcinomas may still test negative for HPV in PCR [3, 13]. 
Besides true negativity, false negativity may occur because 
of either (i) misclassification of the tumour (in particular 
endometrial cancers or metastases of other cancers may be 
misclassified as cervical cancers), (ii) specimen inadequacy, 
(iii) detection method insensitivity, (iv) integration events 
causing disruption of HPV and partial loss of sequences, (v) 









A7 16 16 (108) A6 18 18 (73)
A17 16 16 (622) A12 18 18 (54)
A18 16 16 (16) A13 18 18 (10)
A21 16 16 (1534) A47 18 18 (434)
A26 16 16 (2264) A59 18 18 (16)
A28 16 16 (111) B37 18 18 (82)
A34 16 16 (274) A41 33 33 (1313)
A36 16 16 (12) A53 33 33 (350)
A37 16 16 (729) A58 33 33 (1450)
A43 16 16 (147) A1 45 45 (181)
A44 16 16 (7168) A9 45 45 (44)
A45 16 16 (389) A50 16,33 16 (6), 33 (3219)
A62 16 16 (2270) A60a 16 16 (804), 40 (169)
B1 16 16 (585) A48b 16 33 (8), 73 (86)
B57 16 16 (18098) A33b 16 Negative
A42 58 58 (8450) B40b 16 Negative
A46 58 58 (120) A22b 45 Negative
The numbers in parentheses showthe total number of reads detected. Genotyping HPV results correspond to samples being HPV L1- positive 
by PCR. The letters A and B for sample IDs clarify which samples were subjected to the first and the second sequencing run, respectively. a, 
specimens with partial concordance. b, specimens with discordant results.
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sequence variability in the regions of the virus targeted by 
the detection methods and (vi) the existence of novel HPV 
types that are not detectable by the method used [14]. We had 
carefully re- reviewed all cancer slides to confirm diagnosis 
and assessed specimen adequacy by performing beta- globin 
detection [6], thus options (i) and (ii) above could not have 
caused false- negative observations. By performing an unbi-
ased (not based on methods requiring prior knowledge of the 
sequences being looked for) sequencing, we aimed to increase 
sensitivity and analyse possible biological reasons for why 
these cervical cancers had tested HPV- negative.
The nature of our specimens (FFPE) was not ideal to 
perform RNA sequencing, and the extraction method used 
was not specifically optimized to extract both DNA and 
RNA [7]. Pilot studies were originally performed with DNA 
sequencing for these samples (Nextera library preparation, 
Table 3. HPV detection in ‘apparently HPV- negative’ cervical cancer 
specimens (n=48)






31 7 1/7 Same as reference genome
33 14 13/14 Same as reference genome







58 4 ¼ Same as reference genome
59 2 0/2
62 1 na
73 8 3/8 1 specimen shows 3 




The MGP region coverage column shows how many specimens 
presented reads from the corresponding genotype covering the 
MGP region. Genotypes presented in bold are genotypes that had 
specific probes when genotyping. Note that the total number of 
samples is 48 (not 52) due to 3 specimens presenting multiple HPV 
types (HPV31/58, HPV31/62 and HPV4/53/203).
n, number of specimens where the genotype was found. na, not 
applicable.









<2 % of 
maximum 
reads
HPV4 1 6 6 0
HPV16 20 18 098 6 8
HPV18 6 434 10 0
HPV30 1 14 14 0
HPV31 7 105 8 0
HPV33 19 3219 8 3
HPV35 1 738 738 0
HPV39 1 28 28 0
HPV40 1 169 169 0
HPV45 5 516 14 0
HPV53 1 35 35 0
HPV54 1 272 272 0
HPV56 2 238 76 0
HPV58 6 8450 8 1
HPV59 2 8 6 0
HPV62 1 8 8 0
HPV73 9 561 18 0
HPV203 1 12 12 0
HPV211 1 6 6 0









16 16 2270 E1^E4 (2 reads)
18 18 434 E6* (2 reads)
45 45 181 E6* (2 reads)
45 45 181 E6* (2 reads)
Negative 33 1148 E1^E4 (10 reads)
Negative 35 738 E1^E4 (2 reads)
Negative 33 302 E1^E4 (32 reads)
Negative 54 272 E1^E4 (7 reads)
Negative 33 54 E1^E4 (8 reads)
Negative 45 14 E6* (2 reads)
Negative 45 516 E6* (4 reads)
Negative 73 561 E6* (4 reads)
Each row corresponds to one specimen.
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Rubicon) and the libraries did not reach the quality require-
ments (data not shown), and so we opted not to proceed 
solely with DNA- based sequencing. We chose to proceed 
with the SMARTer Pico Input library preparation protocol, 
which includes primers that amplify both RNA and gDNA 
if such are present in the sample. This was more successful 
and we were able to detect large- molecular- size nucleic 
acids, most probably corresponding to degraded gDNA. We 
do not know if the reads assigned to coding regions were 
from mRNA or DNA. However, the detection of reads with 
known viral splice junctions in 12 specimens is formal proof 
that at least some mRNA was present in these FFPE samples.
In summary, we report that HPV sequences exist in >52 % 
cervical cancer specimens that had previously tested nega-
tive by sensitive HPV PCR. Some sequences were from HPV 
types that we had not tested for (HPV4, HPV62, HPV 203 
and HPV211). Most (29/48) of the PCR- negative cervical 
cancers had no sequences present from the L1 region in the 
samples, which might explain why a PCR method targeting 
L1 failed to detect the HPV. Two samples showed sequence 
variability in the sequences targeted by primers or probes. 
For the remaining 17 cancer specimens, we cannot explain 
why the HPV was not detected. Our previously used method 
has a reported sensitivity of 50 international units of HPV16 
and HPV18 and 500 genome equivalents for the other onco-
genic HPV types [15], suggesting that the difference may 
be attributable to the higher sensitivity of the sequencing. 
Further studies are needed to understand why HPV may 
become difficult to detect in late- stage cancers and how this 
may affect the design and quality assurance of optimal tests 
for HPV- based cervical screening.
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